Literature DB >> 12635138

Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia.

Gema Moreno-Bueno1, David Hardisson, David Sarrió, Carolina Sánchez, Raúl Cassia, Jaime Prat, James G Herman, Manel Esteller, Xavier Matías-Guiu, José Palacios.   

Abstract

Abnormal expression of cadherins and catenins plays a critical role in the initiation and progression of multiple human tumours. This study aimed to evaluate the immunoreactivity of E- and P-cadherin, beta- and gamma-catenin, and p120ctn in premalignant and malignant endometrial lesions and to correlate their membranous expression with clinicopathological features. In addition, we examined whether or not LOH and promoter hypermethylation of the CDH1 gene were associated with E-cadherin expression and clinicopathological variables. Finally, we studied the frequency of beta-catenin mutations in premalignant endometrial lesions. Immunohistochemical staining was performed in 21 atypical endometrial hyperplasias (AEHs), 95 endometrioid carcinomas (EECs), and 33 non-endometrioid carcinomas (NEECs). Reduced E-cadherin expression was observed in 57.8% of the cases, being more frequent in NEECs (87.1%, p = 0.001) and carcinomas of more advanced stage (85.7% of stage III-IV carcinomas, p = 0.01). LOH of CDH1 gene was found in 57.1% of NEECs but only in 22.5% of EECs (p = 0.011) and showed a trend towards association with reduced E-cadherin expression (p = 0.089). CDH1 promoter hypermethylation was found in 21.2% of endometrial carcinomas but was not associated with clinicopathological or immunohistochemical variables. Reduced expression of beta- and gamma-catenin and p120ctn was found in 76.1%, 94.3%, and 63.6% of the cases, respectively, being more frequent in lesions with reduced E-cadherin expression. In addition, beta-catenin, but not gamma-catenin or p120ctn expression, was associated with the histology of the lesion, since it was reduced in 35% of AEHs, 80.3% of EECs, and 96.9% of NEECs (p = 0.000). Mutations in exon 3 of the beta-catenin gene, associated with beta-catenin nuclear expression, were detected in 3 (14.0%) AEH, a frequency similar to that previously reported in this series of ECs. Finally, upregulation of P-cadherin was observed in 28.6% of cases. This alteration was associated with the histology of the lesion, since it was found in 9.5% of AEHs, 27.7% of EECs, and 46.2% of NEECs (p = 0.021). Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12635138     DOI: 10.1002/path.1310

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  35 in total

1.  A novel three-dimensional culture system of polarized epithelial cells to study endometrial carcinogenesis.

Authors:  Núria Eritja; David Llobet; Mónica Domingo; Maria Santacana; Andree Yeramian; Xavier Matias-Guiu; Xavi Dolcet
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

2.  Expression and localization of E-cadherin and β-catenin in uterine carcinosarcoma.

Authors:  Izumi Nishimura; Yoshihiro Ohishi; Yoshinao Oda; Junji Kishimoto; Masafumi Yasunaga; Emi Okuma; Hiroaki Kobayashi; Norio Wake; Masazumi Tsuneyoshi
Journal:  Virchows Arch       Date:  2010-11-03       Impact factor: 4.064

Review 3.  [New features in the 2014 WHO classification of uterine neoplasms].

Authors:  S F Lax
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

Review 4.  DNA methylation in endometrial cancer.

Authors:  Meng Hua Tao; Jo L Freudenheim
Journal:  Epigenetics       Date:  2010-08-16       Impact factor: 4.528

5.  Loss of heterozygosity testing using real-time PCR analysis of single nucleotide polymorphisms.

Authors:  Tamara Cacev; Mladen Jokić; Radan Spaventi; Kresimir Pavelić; Sanja Kapitanović
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-08       Impact factor: 4.553

6.  Role of E-cadherin gene in gall bladder cancer and its precursor lesions.

Authors:  T Padma Priya; V K Kapoor; N Krishnani; Vinita Agrawal; Suraksha Agrawal
Journal:  Virchows Arch       Date:  2010-04-08       Impact factor: 4.064

Review 7.  [Precursor lesions of endometrial carcinoma].

Authors:  S F Lax
Journal:  Pathologe       Date:  2019-02       Impact factor: 1.011

8.  Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?

Authors:  Flora Zagouri; George Bozas; Eftichia Kafantari; Marinos Tsiatas; Nikitas Nikitas; Meletios-A Dimopoulos; Christos A Papadimitriou
Journal:  Obstet Gynecol Int       Date:  2010-02-02

9.  The genomics and genetics of endometrial cancer.

Authors:  Andrea J O'Hara; Daphne W Bell
Journal:  Adv Genomics Genet       Date:  2012-03

Review 10.  The EMT signaling pathways in endometrial carcinoma.

Authors:  Eva Colas; Nuria Pedrola; Laura Devis; Tugçe Ertekin; Irene Campoy; Elena Martínez; Marta Llauradó; Marina Rigau; Mireia Olivan; Marta Garcia; Silvia Cabrera; Antonio Gil-Moreno; Jordi Xercavins; Josep Castellvi; Angel Garcia; Santiago Ramon y Cajal; Gema Moreno-Bueno; Xavier Dolcet; Francesc Alameda; Jose Palacios; Jaime Prat; Andreas Doll; Xavier Matias-Guiu; Miguel Abal; Jaume Reventos
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.